StockNews.com Downgrades Omeros (NASDAQ:OMER) to Sell

Omeros (NASDAQ:OMER) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

A number of other equities analysts have also recently weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Price Performance

Shares of OMER opened at $5.86 on Wednesday. Omeros has a 12 month low of $2.97 and a 12 month high of $13.60. The stock’s 50-day moving average is $8.26 and its two-hundred day moving average is $7.73. The stock has a market cap of $340.26 million, a PE ratio of -2.54 and a beta of 2.35.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period last year, the business earned ($0.15) EPS. On average, research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Omeros by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,110 shares during the period. Truvestments Capital LLC raised its position in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,972 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Omeros by 2.0% in the fourth quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares in the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Omeros by 9.9% during the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 2,600 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.